Etranacogene Dezaparvovec PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
2156583-26-3
Molecular formula
Not available
Molecular weight
Not available
Drug class
Adeno-associated virus serotype 5 (AAV5) gene therapy delivering the factor IX Padua variant (FIX-Padua)
Mechanism of action
AAV5 vector delivers a functional F9 gene encoding the Padua variant of human coagulation factor IX to hepatocytes, enabling endogenous production of factor IX with increased specific activity and supporting haemostasis.
Indications / reported uses
Treatment of adults with haemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis, have a history of life-threatening haemorrhage, or have repeated serious spontaneous bleeding episodes, subject to product-specific criteria
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Etranacogene Dezaparvovec PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Etranacogene Dezaparvovec Permitted Daily Exposure (PDE) report (the Etranacogene Dezaparvovec PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Etranacogene Dezaparvovec Occupational Exposure Limit (OEL) report (the Etranacogene Dezaparvovec OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.